GB201502306D0 - Protein - Google Patents

Protein

Info

Publication number
GB201502306D0
GB201502306D0 GB201502306A GB201502306A GB201502306D0 GB 201502306 D0 GB201502306 D0 GB 201502306D0 GB 201502306 A GB201502306 A GB 201502306A GB 201502306 A GB201502306 A GB 201502306A GB 201502306 D0 GB201502306 D0 GB 201502306D0
Authority
GB
United Kingdom
Prior art keywords
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201502306A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical AB filed Critical Hansa Medical AB
Priority to GB201502306A priority Critical patent/GB201502306D0/en
Publication of GB201502306D0 publication Critical patent/GB201502306D0/en
Priority to MX2017010390A priority patent/MX390806B/es
Priority to MYPI2017001124A priority patent/MY188696A/en
Priority to AU2016217800A priority patent/AU2016217800B2/en
Priority to BR112017017284A priority patent/BR112017017284A2/pt
Priority to PL16707653.8T priority patent/PL3256580T3/pl
Priority to DK16707653.8T priority patent/DK3256580T3/da
Priority to JP2017542896A priority patent/JP6961486B2/ja
Priority to NZ733959A priority patent/NZ733959B2/en
Priority to KR1020177025560A priority patent/KR102524613B1/ko
Priority to EP22174919.5A priority patent/EP4108768A1/en
Priority to PT167076538T priority patent/PT3256580T/pt
Priority to EP16707653.8A priority patent/EP3256580B1/en
Priority to CN202111557859.9A priority patent/CN114231512B/zh
Priority to US15/550,309 priority patent/US10696959B2/en
Priority to PCT/EP2016/053052 priority patent/WO2016128558A1/en
Priority to EA201791773A priority patent/EA035130B1/ru
Priority to CA2976003A priority patent/CA2976003A1/en
Priority to LTEPPCT/EP2016/053052T priority patent/LT3256580T/lt
Priority to SG11201706346QA priority patent/SG11201706346QA/en
Priority to CN201680021601.8A priority patent/CN107532156A/zh
Priority to ES16707653T priority patent/ES2927234T3/es
Priority to ZA2017/05113A priority patent/ZA201705113B/en
Priority to IL253938A priority patent/IL253938B/en
Priority to CL2017002065A priority patent/CL2017002065A1/es
Priority to CONC2017/0009061A priority patent/CO2017009061A2/es
Priority to US16/879,324 priority patent/US11214784B2/en
Priority to AU2021266293A priority patent/AU2021266293B2/en
Priority to US17/644,315 priority patent/US11667905B2/en
Priority to US18/318,455 priority patent/US12359183B2/en
Priority to US19/232,657 priority patent/US20250304937A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
GB201502306A 2015-02-12 2015-02-12 Protein Ceased GB201502306D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein
ES16707653T ES2927234T3 (es) 2015-02-12 2016-02-12 Cisteína proteasa
US15/550,309 US10696959B2 (en) 2015-02-12 2016-02-12 Cysteine protease
PCT/EP2016/053052 WO2016128558A1 (en) 2015-02-12 2016-02-12 Cysteine protease
AU2016217800A AU2016217800B2 (en) 2015-02-12 2016-02-12 Cysteine protease
BR112017017284A BR112017017284A2 (pt) 2015-02-12 2016-02-12 protease de cisteína
PL16707653.8T PL3256580T3 (pl) 2015-02-12 2016-02-12 Proteaza cysteinowa
DK16707653.8T DK3256580T3 (en) 2015-02-12 2016-02-12 Cysteinprotease
JP2017542896A JP6961486B2 (ja) 2015-02-12 2016-02-12 システインプロテアーゼ
NZ733959A NZ733959B2 (en) 2016-02-12 Cysteine protease
KR1020177025560A KR102524613B1 (ko) 2015-02-12 2016-02-12 시스테인 프로테아제
EP22174919.5A EP4108768A1 (en) 2015-02-12 2016-02-12 Cysteine protease
PT167076538T PT3256580T (pt) 2015-02-12 2016-02-12 Cisteína-protease
EP16707653.8A EP3256580B1 (en) 2015-02-12 2016-02-12 Cysteine protease
CN202111557859.9A CN114231512B (zh) 2015-02-12 2016-02-12 半胱氨酸蛋白酶
MX2017010390A MX390806B (es) 2015-02-12 2016-02-12 Proteasa de cisteina.
EA201791773A EA035130B1 (ru) 2015-02-12 2016-02-12 Цистеиновая протеаза
SG11201706346QA SG11201706346QA (en) 2015-02-12 2016-02-12 Cysteine protease
MYPI2017001124A MY188696A (en) 2015-02-12 2016-02-12 Cysteine protease
LTEPPCT/EP2016/053052T LT3256580T (lt) 2015-02-12 2016-02-12 Cisteino proteazė
CA2976003A CA2976003A1 (en) 2015-02-12 2016-02-12 Cysteine protease
CN201680021601.8A CN107532156A (zh) 2015-02-12 2016-02-12 半胱氨酸蛋白酶
ZA2017/05113A ZA201705113B (en) 2015-02-12 2017-07-27 Cysteine protease
IL253938A IL253938B (en) 2015-02-12 2017-08-10 cysteine protease
CL2017002065A CL2017002065A1 (es) 2015-02-12 2017-08-11 Proteasas de cisteína
CONC2017/0009061A CO2017009061A2 (es) 2015-02-12 2017-09-04 Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes
US16/879,324 US11214784B2 (en) 2015-02-12 2020-05-20 Cysteine protease
AU2021266293A AU2021266293B2 (en) 2015-02-12 2021-11-11 Cysteine protease
US17/644,315 US11667905B2 (en) 2015-02-12 2021-12-14 Cysteine protease
US18/318,455 US12359183B2 (en) 2015-02-12 2023-05-16 Cysteine protease
US19/232,657 US20250304937A1 (en) 2015-02-12 2025-06-09 Cysteine protease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein

Publications (1)

Publication Number Publication Date
GB201502306D0 true GB201502306D0 (en) 2015-04-01

Family

ID=52781456

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201502306A Ceased GB201502306D0 (en) 2015-02-12 2015-02-12 Protein

Country Status (23)

Country Link
US (5) US10696959B2 (enExample)
EP (2) EP4108768A1 (enExample)
JP (1) JP6961486B2 (enExample)
KR (1) KR102524613B1 (enExample)
CN (2) CN114231512B (enExample)
AU (2) AU2016217800B2 (enExample)
BR (1) BR112017017284A2 (enExample)
CA (1) CA2976003A1 (enExample)
CL (1) CL2017002065A1 (enExample)
CO (1) CO2017009061A2 (enExample)
DK (1) DK3256580T3 (enExample)
EA (1) EA035130B1 (enExample)
ES (1) ES2927234T3 (enExample)
GB (1) GB201502306D0 (enExample)
IL (1) IL253938B (enExample)
LT (1) LT3256580T (enExample)
MX (1) MX390806B (enExample)
MY (1) MY188696A (enExample)
PL (1) PL3256580T3 (enExample)
PT (1) PT3256580T (enExample)
SG (1) SG11201706346QA (enExample)
WO (1) WO2016128558A1 (enExample)
ZA (1) ZA201705113B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
JP2021519581A (ja) 2018-04-03 2021-08-12 ストライドバイオ，インコーポレイテッド 抗体を回避するウイルスベクター
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
JP7425738B2 (ja) 2018-04-03 2024-01-31 ギンコ バイオワークス インコーポレイテッド 眼組織を標的とするウイルスベクター
AU2020241888A1 (en) 2019-03-21 2021-09-30 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
KR20220083714A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
KR20230152810A (ko) * 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
BR112022015921A2 (pt) 2020-02-14 2022-10-04 Ultragenyx Pharmaceutical Inc Terapia gênica para tratar o transtorno de deficiência de cdkl5
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
WO2021244628A1 (zh) 2020-06-05 2021-12-09 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
JP2023532219A (ja) * 2020-06-18 2023-07-27 上海宝済薬業有限公司 免疫グロブリン分解酵素ＩｄｅＥの突然変異体
AR123288A1 (es) 2020-08-19 2022-11-16 Stridebio Inc Vectores de virus adenoasociados para el tratamiento del síndrome de rett
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
AU2022385450A1 (en) 2021-11-15 2024-06-13 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
US20250145730A1 (en) 2021-12-16 2025-05-08 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-immunoglobulin degrading enzyme-digested fc variant
TW202334183A (zh) 2021-12-22 2023-09-01 大陸商上海寶濟藥業有限公司 免疫球蛋白降解酶ｌｄｅＥ的突變體的用途
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
EP4646476A1 (en) 2023-01-06 2025-11-12 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025072144A1 (en) * 2023-09-27 2025-04-03 Osprey Biopharmaceuticals, Inc. Polypeptides having human igg cleavage activity
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU1686302A (en) 2000-12-21 2002-07-01 Shire Biochem Inc Streptococcus pyogenes antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
CN100379448C (zh) * 2002-11-29 2008-04-09 森永乳业株式会社 蛋白酶抑制剂
EP1601770B1 (en) * 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
PT1901773E (pt) 2005-06-09 2012-06-06 Hansa Medical Ab Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
US7544577B2 (en) 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
EP2190984B1 (en) * 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
AU2008336295B2 (en) * 2007-12-13 2013-07-11 Intervacc Ab Improved immunizing composition
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
EP2394173B1 (en) * 2009-02-09 2015-03-25 Roche Glycart AG Immunoglobulin glycosylation pattern analysis
ES2948841T3 (es) 2010-05-26 2023-09-20 Intervacc Ab Vacuna contra infecciones estreptocócicas basada en proteínas de fusión recombinantes
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Also Published As

Publication number Publication date
ZA201705113B (en) 2024-01-31
NZ733959A (en) 2024-07-26
JP6961486B2 (ja) 2021-11-05
EA035130B1 (ru) 2020-04-30
MY188696A (en) 2021-12-23
IL253938A0 (en) 2017-10-31
MX2017010390A (es) 2017-12-07
AU2021266293B2 (en) 2024-10-03
US12359183B2 (en) 2025-07-15
BR112017017284A2 (pt) 2018-04-17
AU2021266293A1 (en) 2021-12-09
US10696959B2 (en) 2020-06-30
US20200283749A1 (en) 2020-09-10
CL2017002065A1 (es) 2018-04-02
ES2927234T3 (es) 2022-11-03
US11214784B2 (en) 2022-01-04
US20250304937A1 (en) 2025-10-02
PT3256580T (pt) 2022-10-03
LT3256580T (lt) 2022-10-10
KR20170116137A (ko) 2017-10-18
AU2016217800A1 (en) 2017-08-10
CN107532156A (zh) 2018-01-02
SG11201706346QA (en) 2017-09-28
EP3256580A1 (en) 2017-12-20
US20230357741A1 (en) 2023-11-09
EA201791773A1 (ru) 2018-02-28
US11667905B2 (en) 2023-06-06
MX390806B (es) 2025-03-21
PL3256580T3 (pl) 2022-11-28
CO2017009061A2 (es) 2018-01-16
CA2976003A1 (en) 2016-08-18
DK3256580T3 (en) 2022-10-03
KR102524613B1 (ko) 2023-04-21
IL253938B (en) 2020-01-30
US20180023070A1 (en) 2018-01-25
AU2016217800B2 (en) 2021-08-12
JP2018506286A (ja) 2018-03-08
US20220170004A1 (en) 2022-06-02
EP3256580B1 (en) 2022-07-06
CN114231512B (zh) 2025-02-14
CN114231512A (zh) 2022-03-25
WO2016128558A1 (en) 2016-08-18
EP4108768A1 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
IL252696B (en) protein production
GB201415344D0 (en) Protein
HUE050893T2 (hu) Protein
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
GB201520539D0 (en) Peptides
GB2558968B (en) G Proteins
GB201513033D0 (en) Proteins
GB201520536D0 (en) Peptides
GB201520543D0 (en) Peptides
PL3099793T3 (pl) Białko
GB201520541D0 (en) Peptides
GB201522610D0 (en) Protein
GB201520542D0 (en) Peptides
GB201515744D0 (en) Proteins
GB201503778D0 (en) Proteins
GB201515337D0 (en) Protein Expression
GB201414371D0 (en) Protein modification
GB201412797D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201412649D0 (en) Proteins
GB201412648D0 (en) Proteins
GB201520535D0 (en) Peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)